Table 4.
Clinical and treatment characteristics of patients with IC
| Empiric antifungal started when IC suspected | • Fluconazole: 46 (40.4%) |
| • Echinocandins: 66 (59.9%) | |
| • Amphotericin B: 2 (1.8%) | |
| Initiation of antifungal therapy | • Culture based: 19 (16.7%) |
| • Empiric: 54 (47.4%) | |
| • Empiric then culture-based switch: 41 (36%) | |
| Switch to fluconazole in patients on empiric echinocandin after DST availability | • De-escalated: 19 (28.7%) |
| • No change: 47 (71.2%) | |
| Repeat blood cultures for clearance in patients with Candida BSI | • Not done: 5 (4.7%) |
| • Done: 68 (64.7%) | |
| • Not done due to death/discharge against advice: 34 (32.3%) | |
| Clearance achieved with repeat blood culture | • Cleared: 46 (67.6%) |
| • Not cleared: 22 (32.3%) | |
| Echocardiogram for patients with Candida BSI | • Done and reported normal: 59 (56.1%) |
| • Done with infective endocarditis identified: 2 (1.9%) | |
| • Not done (reason not identified): 20 (19%) | |
| • Not done due to death: 16 (15.2%) | |
| • Not done due to DAMA: 8 (7.6%) | |
| Dilated fundus examination | • Done and reported normal: 28 (26.6%) |
| • Not done (reason not identified): 43 (40.9%) | |
| • Not done due to death: 19 (18.0%) | |
| • Not done due to DAMA: 15 (14.2%) |